All procedures were performed according to current standard guidelines. Before PPCI, patients were pre-medicated with aspirin (at least 100 mg) and a loading dose of P2Y12 receptor antagonist. Heparin was administered throughout the PPCI to maintain an activated clotting time of ≥250 s. A glycoprotein IIb/IIIa receptor blocker was administered at the operator’s discretion. Coronary angiography was performed using the standard techniques. Decisions to use thrombectomy devices, intravascular ultrasound, an intra-aortic balloon pump, or percutaneous cardiopulmonary support were made by the operator. STEMI patients implanted with the UBDP-DES (Orsiro™ (Biotronik AG, Bülach, Switzerland); n = 160; from 1 February 2015 to 22 July 2017) were compared to our historic cohort implanted with the DP-DES (Xience V™ [Abbott Vascular, Santa Clara, CA, USA) and Endeavor Resolute™ (Medtronic Vascular, Santa Rosa, CA, USA); n = 196; from 1 June 2008 to 15 September 2010).
Endeavor resolute
Manufactured by Medtronic
Sourced in United States
The Endeavor Resolute is a medical device designed for use in laboratory settings. It is a piece of lab equipment that serves a core function, but its specific intended use should not be interpreted or extrapolated.
Automatically generated - may contain errors
4 protocols using endeavor resolute
1
UBDP-DES vs. DP-DES in STEMI Patients
2
Comparative Coronary Stent Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients were pre-treated with aspirin 300 mg and clopidogrel 300 mg loading dose, followed by 75 mg daily, at least one day prior to the index procedure. During the procedure, an intra-arterial bolus of unfractionated heparin was administered at a dosage of 70 U/kg. All procedures were performed by using zotarolimus-eluting stents (Endeavor ® Resolute; Medtronic, Minneapolis, MN, USA), sirolimus-eluting stents (Coracto™; Alvimedica, Istanbul, Turkey), paclitaxel-eluting stents (Coraxel; Alvimedica) and everolimus-eluting stents (XIENCE V ® ; Abbott Vascular, Santa Clara, CA, USA). After the procedures, all patients were advised to stay on dual antiplatelet therapy for at least one year. All patients were followed up to nine months after the intervention. All patients adhered to dual antiplatelet therapy during the study period.
3
Stent Implantation with Second-Generation DES
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Stent implantation was performed according to current standard techniques and medical guidelines. A total of 1245 lesions were treated with second-generation DESs: 425 everolimuseluting (Xience, Abbot Vascular, Santa Clara, CA, USA; and Promus, Boston Scientific, Marlborough, MA, USA), 399 zotarolimus-eluting (Endeavor Resolute, Medtronic, Minneapolis, MN, USA), 89 sirolimus-eluting (Orsiro, Biotronik, Berlin, Germany), and 332 biolimus-eluting (BioMatrix, Biosensors International, Singapore; and Nobori, Terumo, Tokyo, Japan) stents were used.
All patients were given 300 mg of aspirin in addition to 300 mg to 600 mg of clopidogrel, 180 mg of ticagrelor, or 60 mg of prasugrel before their procedure and were maintained on dual-antiplatelet therapy after DES implantation for at least 6 months. During the intervention, unfractionated heparin was administered to maintain an activated clotting time of more than 250 seconds. Specific details of the intervention, such as lesion predilatation, poststent dilation, and the application of mechanical support or concomitant medication, were left to the discretion of the operator.
All patients were given 300 mg of aspirin in addition to 300 mg to 600 mg of clopidogrel, 180 mg of ticagrelor, or 60 mg of prasugrel before their procedure and were maintained on dual-antiplatelet therapy after DES implantation for at least 6 months. During the intervention, unfractionated heparin was administered to maintain an activated clotting time of more than 250 seconds. Specific details of the intervention, such as lesion predilatation, poststent dilation, and the application of mechanical support or concomitant medication, were left to the discretion of the operator.
4
G2-DES Implantation and Restenosis Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All enrolled patients received G2-DESs implantations in the catheterization centre. The type of G2-DESs included zotarolimus-eluting stents (Endeavor and Endeavor Resolute; Medtronic Vascular, USA), domestic sirolimus-eluting stents (Firebird2; MicroPort Medical, China), everolimus-eluting stents (Xience V and Xience Prime; Abbott Vascular, USA, Promus and Promus Element; Boston Scientific, USA). Stent implantation was performed according to current practice guidelines, and stents were selected by experienced interventional cardiologists. During the procedure, patients received a bolus of 100 IU/kg heparin with a repeated bolus of 2000 IU heparin to maintain the activated clotting time of ≥ 300 s. All patients received aspirin (100 mg/day was administered) and clopidogrel (300 mg loading dose followed by 75 mg/day for at least 12 months). When ISR was diagnosed, patients were treated with re-DES implantation. Procedural success was defined as follows: reduction of stenosis to less than 10% residual narrowing; thrombolysis in myocardial infarction (TIMI) flow grade III; improvement in ischaemic symptoms; and no major procedure related complications [7 (link)].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!